Fas Ligand

Fas Ligand

Fas Ligand Overview

Molecule Name
Soluble Fas ligand
Synonyms
FASLG,ALPS1B,APT1LG1,CD178,CD95L,FASL,TNFSF6
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
CD95L,Fas ligand,SPA,FASLG,Soluble Fas ligand,sFasL,Receptor-binding FasL ectodomain,FasL ICD,TNFSF6,Apoptosis antigen ligand,Tumor necrosis factor ligand superfamily member 6,APL,CD178,Fas Ligand (TNF Superfamily, Member 6),Fas Antigen Ligand,CD95 Ligand,CD95-L,APTL,Mutant Tumor Necrosis Factor Family Member 6,Apoptosis (APO-1) Antigen Ligand 1,CD178 Antigen,ALPS1B,TNLG1A,FasL,Fas Ligand Protein,SPPL2A-processed FasL form,APT1LG1,Tumor Necrosis Factor (Ligand) Superfamily, Member 6,Tumor Necrosis Factor Ligand 1A
Background
Fas ligand is also known as FasL, CD178, CD95L, or TNFSF6, is a homotrimeric type-II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its binding with its receptor induces apoptosis. Fas ligand/receptor interactions play an important role in the regulation of the immune system and the progression of cancer. Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain. Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Apoptosis triggered by Fas-Fas ligand binding plays a fundamental role in the regulation of the immune system. Its functions include:T-cell homeostasis, cytotoxic T-cell activity, immune privilege, maternal tolerance, tumor counterattack. Defective Fas-mediated apoptosis may lead to oncogenesis as well as drug resistance in existing tumors. Germline mutation of Fas is associated with autoimmune lymphoproliferative syndrome (ALPS), a childhood disorder of apoptosis.

Fas Ligand Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AsunerceptCAN-008; APG-101Phase 2 ClinicalApogenix Gmbh
Coronavirus Disease 2019 (COVID-19); Eye Diseases; Glioblastoma; Hematologic Neoplasms; Myelodysplastic Syndromes; Skin Diseases; Solid tumours
Details
XelafaslatideONL-1204Phase 2 ClinicalOnl Therapeutics
Geographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment
Details
M3T01M3T01Phase 1 ClinicalProvidence Health & Services
Solid tumours
Details